Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus
- 21 August 2017
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Abstract
Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide. She continues to be in remission 1 year following the completion of rituximab infusion and is maintained on hydroxychloroquine. This case highlights the need for further research on the use of rituximab and other available biologics in the setting of MAS in order to help guide further alternative treatment decisions.Keywords
This publication has 13 references indexed in Scilit:
- 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2016
- How I treat hemophagocytic lymphohistiocytosis in the adult patientBlood, 2015
- Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 PatientsThe American Journal of Medicine, 2014
- Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosisCurrent Opinion in Rheumatology, 2014
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profilesCytokine, 2013
- Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocolBlood, 2011
- Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesisRheumatology, 2010
- Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 casesRheumatology, 2008
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006